01—Abstract
Summary
Summary of the 8-K filed August 3, 2026. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals reported strong second quarter 2026 results, with total revenue up 12% year over year to $3.33 billiona.
Growth was led by cystic fibrosis (CF) franchise performance, particularly ALYFTREK, which generated $574 millionb in Q2 versus $157 million a year earlier, while TRIKAFTA/KAFTRIO declined to $2.50 billion from $2.55 billion. GAAP net income was $1.10 billion ($4.31 diluted EPS) and non-GAAP net income was $1.21 billion ($4.73 non-GAAP diluted EPS). Operating expenses rose on JOURNAVX launch investment and renal franchise build-out, and the GAAP effective tax rate increased to 21.0% from 19.5%.
Cash and marketable securities reached $13.6 billionc, up from $12.3 billion at year-end 2025, aided by operating cash flow and partly offset by share repurchases. management raised full-year 2026 total revenue guidance to $13.1–$13.2 billion from $12.95–$13.1 billion, while reiterating its expense and tax guidance. The guidance excludes the pending acquisition of Crinetics Pharmaceuticals, announced in July at $85.00 per share in cash for an equity value of roughly $10.0 billion (about $8.8 billion net of acquired cash), with closing expected in Q3 2026. That deal would add rare endocrine diseases as a fifth pillar, and management plans updated 2026 guidance after closing.
Key near-term catalysts include the povetacicept IgAN PDUFA date of November 30, 2026, the AMPLIFIED Phase 2 inaxaplin data this fall, VX-828 and VX-670 data in the second half of 2026, and the Crinetics closing. Investors should note that the filing itself is a press release furnished under Item 2.02 and is not deemed filed for Section 18 purposes.
02—Key points
Key Highlights
- Q2 2026 total revenue of $3.33 billion, up 12% year over year, driven by CF franchise growth and early contributions from CASGEVY and JOURNAVX
- ALYFTREK revenue of $573.6 million in Q2 2026 versus $156.8 million in Q2 2025, while TRIKAFTA/KAFTRIO declined to $2.50 billion from $2.55 billion
- Full-year 2026 total revenue guidance raised to $13.1–$13.2 billion from $12.95–$13.1 billion; expense and non-GAAP tax guidance unchanged
- GAAP diluted EPS of $4.31 and non-GAAP diluted EPS of $4.73 in Q2 2026, versus $3.99 and $4.52 a year earlier
- CASGEVY revenue of $76.4 million (up 151% year over year) and JOURNAVX revenue of $49.6 million (more than quadrupled) in Q2 2026
- Pending acquisition of Crinetics Pharmaceuticals at $85.00 per share in cash (~$10.0 billion equity value), expected to close in Q3 2026 and excluded from current guidance
- Cash and marketable securities of $13.6 billion at June 30, 2026, up from $12.3 billion at December 31, 2025
03—Questions
Frequently Asked Questions
Did Vertex raise its 2026 revenue outlook?
Yes. Vertex raised full-year 2026 total revenue guidance to $13.1–$13.2 billion from $12.95–$13.1 billion. The guidance includes $500 million or more in non-CF revenue from CASGEVY and JOURNAVX and about 150 basis points of benefit from foreign exchange, net of hedging. It does not yet reflect the Crinetics acquisition.
Are operating expenses rising faster than revenue?
In Q2 2026, combined GAAP R&D, acquired IPR&D and SG&A expenses rose to about $1.6 billion from $1.4 billion, and non-GAAP expenses rose to $1.43 billion from $1.24 billion. Growth was driven by JOURNAVX launch investment and the renal franchise build-out. Full-year expense guidance was held steady, with combined GAAP R&D, AIPR&D and SG&A of $6.3–$6.45 billion.
What is the Crinetics deal and how will it affect Vertex?
Vertex agreed to acquire Crinetics for $85.00 per share in cash, an equity value of about $10.0 billion, or roughly $8.8 billion net of acquired cash. The deal is expected to close in Q3 2026, subject to customary conditions. It would add rare endocrine diseases as a fifth therapeutic pillar, and Vertex will update 2026 guidance after closing.
What are the key upcoming regulatory and clinical catalysts?
The most notable is the FDA PDUFA target action date of November 30, 2026 for povetacicept for accelerated approval in adults with IgAN. Other catalysts include AMPLIFIED Phase 2 inaxaplin data this fall, VX-828 proof-of-concept data and VX-670 DM1 data in the second half of 2026, and an AMPLITUDE interim analysis in early 2027.
Why did GAAP tax rate and net income change?
The GAAP effective tax rate rose to 21.0% in Q2 2026 from 19.5% a year earlier. GAAP net income was $1.10 billion versus $1.03 billion, while non-GAAP net income was $1.21 billion versus $1.17 billion. Management guides only to a non-GAAP tax rate of 19.5%–20.5% and does not guide to a GAAP rate because of stock-based compensation excess tax benefits and possible discrete items.
04—Continue